Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $53.90.

Several equities research analysts recently weighed in on CLDX shares. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. UBS Group decreased their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Morgan Stanley dropped their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th.

Institutional Trading of Celldex Therapeutics

Large investors have recently made changes to their positions in the stock. Deep Track Capital LP purchased a new position in Celldex Therapeutics in the 4th quarter worth $38,919,000. Point72 Asset Management L.P. increased its stake in Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after purchasing an additional 847,264 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Celldex Therapeutics by 23.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after acquiring an additional 676,771 shares in the last quarter. Nuveen LLC purchased a new position in shares of Celldex Therapeutics in the 1st quarter valued at $7,789,000. Finally, Millennium Management LLC increased its holdings in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock valued at $7,259,000 after acquiring an additional 306,330 shares during the period.

Celldex Therapeutics Price Performance

Shares of CLDX traded down $0.30 during mid-day trading on Tuesday, hitting $19.55. 352,282 shares of the company's stock were exchanged, compared to its average volume of 907,785. The company has a 50-day simple moving average of $18.88 and a 200 day simple moving average of $22.23. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $47.00. The company has a market cap of $1.30 billion, a PE ratio of -7.61 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.